News Search Results
Sep 10, 2025, 15:07 ET Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey
international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India
More news about: Biocon
Sep 10, 2025, 14:30 ET NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced positive initial results from its collaboration with
More news about: NeuroSense
Sep 10, 2025, 09:30 ET Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries
"Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale production of high-purity, highly active free-form soybean phospholipids. This breakthrough was
More news about: Shineco,Inc.
Sep 10, 2025, 08:48 ET Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Sep 10, 2025, 08:43 ET Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Sep 10, 2025, 08:30 ET Tumor Microenvironment Analysis Using Curated Data and Modeling, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 10, 2025, 08:30 ET Patient Recruitment Strategies: Empowering Patients Through Accessible Information, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 10, 2025, 07:47 ET Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update
Sept. 10, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system
More news about: Intensity Therapeutics Inc.
Sep 10, 2025, 07:00 ET Noxilizer Expands Access to Commercial-Scale Nitrogen Dioxide Terminal Sterilization Capacity with $30 Million in Growth Capital Led by NewVale Capital
sterilization platform plays a pivotal role in addressing the urgent market demand for alternatives to ethylene oxide ("EtO"), with leading pharmaceutical, biotechnology, and medical device companies already relying on Noxilizer to sterilize critical drug-device combination products. This growth financing will expand
More news about: Noxilizer, Inc.
Sep 10, 2025, 06:00 ET Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
hurdle required for closing the merger. Upon completion, the combined company — to be known as NewCelX Ltd. — will remain a publicly traded biotechnology company listed on Nasdaq under the ticker "NCEL", uniting Kadimastem's proprietary cell therapy platforms with NLS's expertise in small-molecule
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Sep 10, 2025, 06:00 ET Essa Pharma Inc. to Adjourn Special Meeting to September 29, 2025
September 10, 2025 to consider and approve the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Common Shares (the "Transaction" or the "Arrangement"). ESSA is
More news about: ESSA Pharma Inc.
Sep 09, 2025, 22:49 ET ImmVira Announces First-in-Human Data of Engineered Exosome MVR-EX105 for Fat Reduction and Muscle Preservation by Topical Application at 2025 Annual Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders
professional-grade at-home solutions for localized fat reduction. About ImmVira ImmVira is a global leading clinical-stage biotechnology company that is powered by proprietary biological engineering technology, and is dedicated to the discovery, development, manufacture and commercialization
More news about: ImmVira
![Partner Therapeutics Receives EMA Approval of IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Hematopoietic Sub-syndrome of Acute Radiation Syndrome [H-ARS])](https://mma.prnewswire.com/media/633165/PTx_updated_logo.jpg?w=300){kind=logo}
Sep 09, 2025, 13:42 ET Partner Therapeutics Receives EMA Approval of IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Hematopoietic Sub-syndrome of Acute Radiation Syndrome [H-ARS])
https://ec.europa.eu/health/documents/community-register/2025/20250821166908/anx_166908_en.pdf. ABOUT PARTNER THERAPEUTICSPartner Therapeutics, Inc. (PTx), an integrated biotechnology company, focuses on development and commercialization of late-stage therapeutics to improve health outcomes in treatment serious diseases and to
More news about: Partner Therapeutics, Inc.
Sep 09, 2025, 11:22 ET Marshmallow Market Is Expected To Reach US$3.46 Billion By 2031 At CAGR Of 7.4% During The Forecast Period |The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Sep 09, 2025, 11:00 ET TCI Biotech Strengthens Global Leadership Team with Appointment of Sales VP Tony Hatori and Strategic Consultant Alan Roberts
SALT LAKE CITY, Utah, Sept. 9, 2025 /PRNewswire/ -- TCI, a global biotechnology leader in health and wellness innovation, today announced key leadership appointments to accelerate its international growth. Tony
More news about: TCI; TCI Bio
Sep 09, 2025, 10:43 ET GBI Biomanufacturing Partners with NanoRetinal to Advance Vision-Restoring Therapy for Inherited Retinal Diseases
analytical characterization, and GMP manufacturing of complex biologics. NanoRetinal NanoRetinal is a biotechnology company dedicated to developing life-changing treatments for patients with IRD through applications of their proprietary nanoparticulate technology.
More news about: GBI Biomanufacturing
Sep 09, 2025, 10:05 ET 3D Printing Market to Reach USD 210.5 Billion by 2035 | Growing at a CAGR of 24.25% - Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Sep 09, 2025, 10:01 ET Whey Powder Market Size is Expected to Reach US$5.80 Billion By 2031 at CAGR Of 5.5% During The Forecast Period | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Sep 09, 2025, 09:14 ET NeuroKaire launches first-of-its-kind clinical test in the US, expected to dramatically reduce the 'trial and error' approach to finding the right antidepressant
fewer side effects, lower dosing, and the elimination of arduous trial-and-error treatment protocols. NeuroKaire also enables pharmaceutical and biotechnology companies to bring precision medicine into drug development throughout the developmental pipeline across psychiatry and neurology. For more information
More news about: NeuroKaire
Sep 09, 2025, 09:00 ET Hydrosome Labs Reveals Promising Fermentation Breakthrough Using Ultrafine Bubbles
Hydrosome Labs, a Chicago-based biotechnology company pioneering ultrafine bubble (UFB) technology, today announced new findings from a study with Biocell Energetics, a venture from the
More news about: Hydrosome Labs
Sep 09, 2025, 09:00 ET Neuvian Skincare Granted Breakthrough U.S. Patent for Dual Peptide Skin Technology
Skincare:Founded in 2024 and based in Miami, FL, Neuvian Skincare is a beauty-tech brand applying organic chemistry, biotechnology, and
More news about: Neuvian Skincare
Sep 09, 2025, 09:00 ET iRegene Therapeutics Secures Series B+ Financing Following FDA Fast Track Designation for its Flagship Product NouvNeu001
9, 2025 /PRNewswire/ -- iRegene Therapeutics (Chengdu) Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, announced on September 4th the successful completion
More news about: iRegene therapeutics
Sep 09, 2025, 09:00 ET MATTER OF FACT AWARDED U.S. PATENT FOR VITAMIN C STABILIZATION TECHNOLOGY
entrepreneurs are known for their work on Olaplex and K18 Hair, and as brand architects behind Goddess Maintenance Co.'s Biotech Blowout. Focusing on biotechnology, they foster advancements in skin and hair care. Next8 Investments supports emerging beauty and biotech founders while pioneering technologies in
More news about: MATTER OF FACT
Sep 09, 2025, 09:00 ET Kytopen Announces Collaboration with BlueWhale Bio to Revolutionize Cell Therapy Manufacturing
across a range of cell types, payloads, and therapeutic applications. Kytopen has recently disclosed strategic partnerships with industry-leading biotechnology companies, contract development and manufacturing organizations (CDMOs), and cell therapy-focused medical centers. Kytopen continues to engage strategic
More news about: Kytopen
Sep 09, 2025, 08:51 ET TheWell Bioscience Launches VitroGel® NEURON, a First-Of-Its-Kind Synthetic Hydrogel for Superior 3D, 2D Neuronal Cell Culture and Beyond
[email protected]. About TheWell Bioscience Inc. TheWell Bioscience Inc. is a pioneering biotechnology company dedicated to advancing 3D cell culture and tissue engineering through the innovative xeno-free VitroGel® hydrogel platforms. The VitroGel®
More news about: TheWell Bioscience Inc.